{"nctId":"NCT00561821","briefTitle":"Efficacy and Safety Study of Org 50081 (Esmirtazapine) in Elderly Participants (P05709)","startDateStruct":{"date":"2007-11-20","type":"ACTUAL"},"conditions":["Insomnia","Sleep Initiation and Maintenance Disorders","Mental Disorders","Dyssomnias","Sleep Disorders"],"count":538,"armGroups":[{"label":"Esmirtazapine 0.5 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Esmirtazapine","Drug: Placebo"]},{"label":"Esmirtazapine 1.5 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Esmirtazapine","Drug: Placebo"]},{"label":"Esmirtazapine 3.0 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Esmirtazapine","Drug: Placebo"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Esmirtazapine","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* are at least 65 years of age at screening;\n* sign written informed consent after the scope and\n\nnature of the investigation have been explained to\n\nthem, before screening evaluations;\n\n* are able to speak, read and understand the language of\n\nthe investigator, study staff (including raters) and the\n\ninformed consent form, and possess the ability to\n\nrespond to questions, follow instructions and complete\n\nquestionnaires;\n\n* have demonstrated capability to independently\n\ncomplete the LogPad questionnaires and have\n\ncompleted the questionnaires at least 6 out of 7 days of\n\nthe week preceding randomization;\n\n* have a regular sleep pattern, meaning bedtime regularly\n\noccurs between 2100 hours and 2400 hours, with no more variation\n\nfrom these boundaries than 2 times/ week, with 5-8.5\n\nhours in bed;\n\n* have a documented diagnosis of chronic primary\n\ninsomnia, defined as fulfillment of the Diagnostic and Statistical Manual of Mental Disorders IV - Text Revision (DSM-IV-TR) criteria\n\nfor primary insomnia (DSM-IV-TR 307.42) with a duration\n\nof \\>= 1 month; fulfill the following PSG criteria on the\n\ntwo screening/baseline PSG nights:\n\n* average Total Sleep Time (TST) \\< 6.5 h (and each night greater than or\n\nequal to 3 h and \\< 7 h),\n\n* average WASO greater than or equal to 45 minutes\n\n(and each night greater than or equal to 30 min),\n\n* average Latency to Persistent Sleep (LPS) 15 min (and each night greater than or\n\nequal to 10 min).\n\nExclusion Criteria:\n\n* have other sleep disorders (DSM-IV-TR), such as sleep\n\nrelated breathing disorders Apnea-Hypopnea Index (AHI) greater than or equal\n\nto 15), Periodic Leg Movements with Arousals Index (PLMAI)\n\ngreater than or equal to 10), restless leg syndrome,\n\nnarcolepsy, circadian sleep wake rhythm disorders,\n\nRapid Eye Movement (REM) behavioral disorder or any parasomnia;\n\n* have any significant medical or DSM-IV-TR\n\npsychiatric illness causing the sleep disturbances;\n\n* currently meet diagnostic criteria for DSM-IV-TR\n\ndepression Major Depressive Disorder (MDD) or have been diagnosed and treated\n\nfor MDD within the last 2 years;\n\n* have a history of bipolar disorder, a history of suicide attempt or a family history of suicide. A family history of suicide is defined as any history of suicide in the first and second degree family (parents, siblings, grandparents, or offspring), or a pattern of completed suicides (more than one) in the third degree family (aunts, uncles, nieces and nephews);\n* have a history or signs of dementia or other serious\n\ncognitive impairment, as defined by a score of less than\n\n26 on the Mini-Mental State Examination;\n\n* have a significant, unstable medical illness e.g. acute or\n\nchronic pain, hepatic, renal, metabolic or cardiac\n\ndisease;\n\n* had serious head injury or stroke within the past year,\n\nor a history of (non-febrile) seizures;\n\n* have clinically relevant electrocardiogram (ECG) abnormalities at\n\nscreening, as judged by the investigator;\n\n* have clinically relevant abnormal hematology or\n\nbiochemistry values at screening, as judged by the\n\ninvestigator;\n\n* have DSM-IV-TR substance abuse or DSM-IV-TR\n\naddiction within the last year;\n\n* drink more than 2 alcoholic drinks in a day. One drink is approximately equal to: 12 oz or 360 ml of beer (regular or light), or 4 oz or 120 ml of red or white wine, or 2 oz or 60 ml of desert wine (e.g. port, sherry), or 12 oz or 360 ml of wine cooler (regular or light), or 1 oz or 30 ml or spirits (80 to 100 proof, e.g. whiskey, vodka);\n* are routinely sleeping during daytime (napping) for more than 20 minutes per day, 3 days or more per week;\n* are night workers or rotating shift workers currently, or in the past 6 months\n* use of psychotropic drugs affecting sleep within two weeks prior to randomization (fluoxetine: five weeks);\n* use of concomitant medication affecting sleep (e.g. anxiolytics, sedatives, antidepressants, antipsychotics, centrally active sedating antihistamines, central nervous system (CNS)\n\nstimulants, alpha-2-antagonists, respiratory stimulants and decongestants);\n\n* smoke \\> 15 cigarettes per day and/or can not abstain from smoking during the night;\n* drink excessive amounts of caffeinated beverages/day (more than 500 mg caffeine per day);\n* have a body mass index (BMI) \\>= 36;\n* have a positive urine drug screen at screening or at baseline;\n* have a known hypersensitivity to mirtazapine or to any of the excipients;","healthyVolunteers":false,"sex":"ALL","minimumAge":"65 Years","stdAges":["OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Average Wake Time After Sleep Onset Measured by Polysomnography","description":"Wake time after sleep onset (WASO) is the total time awake between sleep onset and \"lights on\"; i.e. from the onset of persistent sleep until the end of the 8-hour polysomnography (PSG) recording. PSG assesses the quality of sleep by monitoring brain waves, breathing, heart function, muscle activity and eye movement. PSG measurements of WASO (observed data only) taken during the 16-day double-blind treatment period, over days 1 and 2 and days 15 and 16, were averaged.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"80.3","spread":"36.5"},{"groupId":"OG001","value":"79.6","spread":"30.7"},{"groupId":"OG002","value":"74.8","spread":"28.0"},{"groupId":"OG003","value":"109.8","spread":"42.1"}]}]}]},{"type":"SECONDARY","title":"Average Latency to Persistent Sleep Measured by Polysomnography","description":"Latency to Persistent Sleep (LPS) is the time from lights out to the first 20 consecutive epochs scored as sleep by PSG. PSG assesses the quality of sleep by monitoring brain waves, breathing, heart function, muscle activity and eye movement. PSG measurements of LPS (observed data only) taken during the 16-day double-blind treatment period, over days 1 and 2 and days 15 and 16, were averaged.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"32.3","spread":"24.8"},{"groupId":"OG001","value":"30.7","spread":"23.0"},{"groupId":"OG002","value":"29.3","spread":"22.8"},{"groupId":"OG003","value":"37.1","spread":"25.7"}]}]}]},{"type":"SECONDARY","title":"Average Total Sleep Time Measured by Polysomnography","description":"Total sleep time (TST) is the sleep time recorded by PSG. PSG assesses the quality of sleep by monitoring brain waves, breathing, heart function, muscle activity and eye movement. PSG measurements of TST (observed data only) taken during the 16-day double-blind treatment period, over days 1 and 2 and days 15 and 16, were averaged.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"374.1","spread":"39.9"},{"groupId":"OG001","value":"376.2","spread":"34.9"},{"groupId":"OG002","value":"383.4","spread":"35.7"},{"groupId":"OG003","value":"338.7","spread":"45.8"}]}]}]},{"type":"SECONDARY","title":"Average Number of Awakenings Measured by Polysomnography","description":"Number of awakenings (NAW) was measured by PSG. PSG assesses the quality of sleep by monitoring brain waves, breathing, heart function, muscle activity and eye movement. PSG measurements of NAW (observed data only) taken during the 16-day double-blind treatment period, over days 1 and 2 and days 15 and 16, were averaged.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13.5","spread":"5.4"},{"groupId":"OG001","value":"13.4","spread":"4.7"},{"groupId":"OG002","value":"13.5","spread":"4.7"},{"groupId":"OG003","value":"12.1","spread":"4.8"}]}]}]},{"type":"SECONDARY","title":"Average Wake Time After Sleep Onset in the First Quarter of the Night Measured by Polysomnography","description":"Wake time after sleep onset (WASO) is the total time awake between sleep onset and \"lights on\"; i.e. from the onset of persistent sleep until the end of the 8-hour PSG recording. WASO was recorded in the first quarter of the night, for at most 2 hours, by PSG. PSG assesses the quality of sleep by monitoring brain waves, breathing, heart function, muscle activity and eye movement. PSG measurements of WASO (observed data only) taken during the 16-day double-blind treatment period, over days 1 and 2 and days 15 and 16, were averaged.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"34.5","spread":"17.4"},{"groupId":"OG001","value":"33.7","spread":"16.2"},{"groupId":"OG002","value":"31.2","spread":"15.6"},{"groupId":"OG003","value":"40.6","spread":"20.0"}]}]}]},{"type":"SECONDARY","title":"Average Wake Time After Sleep Onset in the Second Quarter of the Night Measured by Polysomnography","description":"Wake time after sleep onset (WASO) is the total time awake between sleep onset and \"lights on\"; i.e. from the onset of persistent sleep until the end of the 8-hour PSG recording. WASO was recorded in the second quarter of the night, for at most 2 hours, by PSG. PSG assesses the quality of sleep by monitoring brain waves, breathing, heart function, muscle activity and eye movement. PSG measurements of WASO (observed data only) taken during the 16-day double-blind treatment period, over days 1 and 2 and days 15 and 16, were averaged.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20.1","spread":"11.7"},{"groupId":"OG001","value":"19.2","spread":"11.4"},{"groupId":"OG002","value":"18.9","spread":"10.4"},{"groupId":"OG003","value":"25.9","spread":"13.7"}]}]}]},{"type":"SECONDARY","title":"Average Wake Time After Sleep Onset in the Third Quarter of the Night Measured by Polysomnography","description":"Wake time after sleep onset (WASO) is the total time awake between sleep onset and \"lights on\"; i.e. from the onset of persistent sleep until the end of the 8-hour PSG recording. WASO was recorded in the third quarter of the night, for at most 2 hours, by PSG. PSG assesses the quality of sleep by monitoring brain waves, breathing, heart function, muscle activity and eye movement. PSG measurements of WASO (observed data only) taken during the 16-day double-blind treatment period, over days 1 and 2 and days 15 and 16, were averaged.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20.5","spread":"12.0"},{"groupId":"OG001","value":"21.3","spread":"11.6"},{"groupId":"OG002","value":"19.1","spread":"10.4"},{"groupId":"OG003","value":"31.9","spread":"18.5"}]}]}]},{"type":"SECONDARY","title":"Average Wake Time After Sleep Onset in the Fourth Quarter of the Night Measured by Polysomnography","description":"Wake time after sleep onset (WASO) is the total time awake between sleep onset and \"lights on\"; i.e. from the onset of persistent sleep until the end of the 8-hour PSG recording. WASO was recorded in the fourth quarter of the night, for at most 2 hours, by PSG. PSG assesses the quality of sleep by monitoring brain waves, breathing, heart function, muscle activity and eye movement. PSG measurements of WASO (observed data only) taken during the 16-day double-blind treatment period, over days 1 and 2 and days 15 and 16, were averaged.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"30.9","spread":"17.6"},{"groupId":"OG001","value":"29.7","spread":"13.5"},{"groupId":"OG002","value":"27.4","spread":"14.9"},{"groupId":"OG003","value":"42.4","spread":"23.2"}]}]}]},{"type":"SECONDARY","title":"Average Number of Stage Shifts to Stage 1 or Wake Measured by Polysomnography","description":"Number of stage shifts to stage 1 of sleep or to awaken was measured by PSG. A stage shift is the transition measured by PSG between various sleep stages. PSG assesses the quality of sleep by monitoring brain waves, breathing, heart function, muscle activity and eye movement. PSG measurements of the number of stage shifts (observed data only) taken during the 16-day double-blind treatment period, over days 1 and 2 and days 15 and 16, were averaged.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"51.8","spread":"16.0"},{"groupId":"OG001","value":"50.6","spread":"15.3"},{"groupId":"OG002","value":"51.3","spread":"16.1"},{"groupId":"OG003","value":"44.0","spread":"15.7"}]}]}]},{"type":"SECONDARY","title":"Average Subjective Total Sleep Time Based on Sleep Diary","description":"Total Sleep Time (TST) is a subjective time (observed data only) recorded daily by the participant in an electronic diary, that was averaged over the entire 16-day, double-blind treatment period.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"364.4","spread":"61.4"},{"groupId":"OG001","value":"357.3","spread":"73.2"},{"groupId":"OG002","value":"368.8","spread":"63.9"},{"groupId":"OG003","value":"339.9","spread":"52.7"}]}]}]},{"type":"SECONDARY","title":"Average Subjective Sleep Latency Based on Sleep Diary","description":"Sleep latency (SL) is the time taken to fall asleep (observed data only) recorded daily by the participant in an electronic diary, that was averaged over the entire 16-day, double-blind treatment period.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"51.6","spread":"48.9"},{"groupId":"OG001","value":"53.1","spread":"39.9"},{"groupId":"OG002","value":"50.5","spread":"43.0"},{"groupId":"OG003","value":"46.5","spread":"26.3"}]}]}]},{"type":"SECONDARY","title":"Average Subjective Number of Awakenings Based on Sleep Diary","description":"Number of awakenings between sleep onset and final awakening (NAW) is a subjective number (observed data only) recorded daily by the participant in an electronic diary, that was averaged over the entire 16-day, double-blind treatment period.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.9","spread":"1.2"},{"groupId":"OG001","value":"2.2","spread":"1.8"},{"groupId":"OG002","value":"2.1","spread":"1.3"},{"groupId":"OG003","value":"1.9","spread":"1.0"}]}]}]},{"type":"SECONDARY","title":"Average Subjective Wake Time After Sleep Onset Based on Sleep Diary","description":"Wake Time after Sleep Onset (WASO) is after falling asleep initially, the subjective time that the participant was awake during the night. Daily recordings by the participant in an electronic diary (observed data only), were averaged over the entire 16-day, double-blind treatment period.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"58.4","spread":"38.9"},{"groupId":"OG001","value":"70.3","spread":"53.1"},{"groupId":"OG002","value":"62.2","spread":"45.4"},{"groupId":"OG003","value":"81.7","spread":"50.0"}]}]}]},{"type":"SECONDARY","title":"Average Subjective Quality of Sleep Based on Sleep Diary","description":"Quality of Sleep (QS) is a subjective number on a Visual Analog Scale ranging from 0 to 100, where very poor is rated at 0, up to excellent, rated at 100. Daily recordings by the participant in an electronic diary (observed data only) were averaged over the entire 16-day, double-blind treatment period.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"57.8","spread":"16.1"},{"groupId":"OG001","value":"56.7","spread":"17.0"},{"groupId":"OG002","value":"58.0","spread":"17.4"},{"groupId":"OG003","value":"54.8","spread":"18.1"}]}]}]},{"type":"SECONDARY","title":"Average Subjective Satisfaction of Sleep Duration Based on Sleep Diary","description":"Satisfaction of Sleep Duration (SSD) is a subjective number on a Visual Analog Scale ranging from 0 to 100, where very unsatisfied is rated at 0, up to fully satisfied, rated at 100. Daily recordings by the participant in an electronic diary (observed data only) were averaged over the entire 16-day, double-blind treatment period.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"57.8","spread":"16.0"},{"groupId":"OG001","value":"56.8","spread":"16.4"},{"groupId":"OG002","value":"58.1","spread":"17.2"},{"groupId":"OG003","value":"54.0","spread":"17.0"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With an Adverse Event During the 16 Day, Double-blind Treatment Period","description":"An Adverse Event (AE) is any untoward occurrence in a participant who is administered any pharmaceutical product, and which does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding) symptom, or disease temporarily associated with the use of an investigational medicinal product (IMP), whether or not it is related to the IMP.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"48","spread":null},{"groupId":"OG001","value":"54","spread":null},{"groupId":"OG002","value":"56","spread":null},{"groupId":"OG003","value":"40","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Who Discontinued Treatment Due to an Adverse Event During the 16 Day, Double-blind Treatment Period","description":"An AE is any untoward occurrence in a participant who is administered any pharmaceutical product, and which does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding) symptom, or disease temporarily associated with the use of an IMP, whether or not it is related to the IMP.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"1","spread":null},{"groupId":"OG003","value":"1","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":132},"commonTop":["Somnolence","Fatigue","Dizziness"]}}}